Nuclein
Private Company
Funding information not available
Overview
Nuclein is a private diagnostics company commercializing a rapid, point-of-care PCR system called DASH. The platform distinguishes itself by offering lab-quality molecular results in 15 minutes with minimal hands-on time, room-temperature stable cartridges, and a small, affordable instrument footprint suitable for decentralized care settings. With an initial FDA-cleared product for COVID-19 and flu, the company is positioned to expand its test menu into other infectious disease areas, targeting the growing demand for fast, accurate diagnostics at the point of care.
Technology Platform
The DASH Rapid PCR System is a compact, sample-to-answer, point-of-care PCR platform. It automates sample prep, extraction, amplification, and detection to deliver results in 15 minutes. Key features include room-temperature stable, multiplex-capable cartridges, minimal hands-on time, and cloud connectivity.
Opportunities
Risk Factors
Competitive Landscape
Nuclein competes in the rapid point-of-care molecular diagnostics market against large, established players like Cepheid (GeneXpert), BioFire (BioFire FilmArray), Abbott (ID NOW), and LumiraDx. Its key differentiators are the 15-minute run time, room-temperature cartridge storage, and emphasis on affordability, but it currently has a much more limited test menu than its competitors.